Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02302976 · ClinicalTrials.gov registry record · Phase 1
GLP-1 Agonism for Blocking Cocaine Euphoria and Self-Administration
A Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT02302976 is a Phase 1 study that has completed, run by Yale University. The registered enrollment target is 13 participants.
The verdict
NCT02302976, a Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
The investigators plan to explore the effects of acute pre-treatment with the glucagon like peptide-1 (GLP-1) agonist, exenatide versus placebo, on the subjective (e.g., euphoric) and behavioral effects (e.g., self-administration) of cocaine in experienced, non-treatment seeking users of the drug. Additionally, the investigators plan to explore the effects of sub-chronic (5-day) treatment with exenatide as compared to placebo on the subjective (e.g., euphoric) and behavioral (self-administration) effects of cocaine in experienced, non-treatment seeking users of the drug.
Interventions
- DRUG placebo
- DRUG exenatide
- DRUG cocaine hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2014-11 |
| Est. Completion | 2018-08-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02302976
The ClinicalTrials.gov registry entry for NCT02302976 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT02302976 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02302976 about?
NCT02302976 is a clinical study titled "GLP-1 Agonism for Blocking Cocaine Euphoria and Self-Administration". The investigators plan to explore the effects of acute pre-treatment with the glucagon like peptide-1 (GLP-1) agonist, exenatide versus placebo, on the subjective (e.g., euphoric) and behavioral effects (e.g., self-administration) of cocaine in experienced, non-treatment seeking users of the drug. A...
What is the current status of trial NCT02302976?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2014-11. Estimated completion is 2018-08-01.
What interventions are being tested in trial NCT02302976?
The interventions under investigation include: placebo (DRUG), exenatide (DRUG), cocaine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT02302976?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.